Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 51

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 51
---
 ninety (90) days following the Closing Date, the Company shall not effect or enter into an agreement to effect any issuance by the Company of Common Stock or Common
Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction, other than in connection with an Exempt Issuance or as set forth in the SEC Documents as of the date of this Agreement. The Investor shall be entitled to
seek injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required.
Notwithstanding the foregoing provisions of this , until such time as this Agreement has been terminated pursuant to , the Company shall be permitted to enter into an
additional equity line of credit provided that the Company shall not be permitted to issue any securities under any such additional equity line of credit unless:

(i) the maximum discount to the daily VWAP applicable to such sales shall not exceed four percent (4%);

(ii) the maximum number of shares permitted to be sold thereunder on any Trading Day shall not exceed such number of shares
of Common Stock as would be issuable in accordance with the VWAP Purchase Maximum Amount as defined herein;

(iii) the
Company shall not deliver, and shall not be permitted to deliver, any purchase notice or equivalent instruction under such other agreement on any Trading Day on which the Company has delivered a VWAP Purchase Notice to the Investor hereunder through
and including the later of the (A) VWAP Purchase Date and (B) the date on which the Investor has received all of such Shares as DWAC Shares (or, in lieu of such DWAC Shares, has received the Cover Price from the Company therefor); and

(iv) such arrangement does not include economic or structural rights that are more favorable to the counterparty thereto than
those provided to the Investor under this Agreement, including with respect to the payment of a commitment fee or issuance of commitment shares, issuance of warrants, or grant of termination rights or resale registration rights.

Section6.7 . The Company shall take all steps necessary to preserve and
continue the corporate existence of the Company; provided, however, that, except as provided in , nothing in this Agreement shall be deemed to prohibit the Company from engaging in any Fundamental Transaction
with another Person. For the avoidance of doubt, nothing in this shall in any way limit the Company’s right to terminate this Agreement in accordance with (subject in
all